Our Mission
To improve the lives of children living with a Lysosomal Storage Disease (LSD). We remain laser focused on accelerating the discovery and development of treatment options for these diseases with significant unmet medical needs.
Our current focus is on Acid Sphingomyelinase Deficiency (ASMD), also referred to as Niemann Pick Disease Types A & B (NPA & NPB).
-
Babies born with a Lysosomal Storage Disease each day
48
-
Identified Lysosomal Storage Diseases (LSD's)
50
-
1 in 7700 Children are diagnosed with a LSD
7700
-
FDA approved treatment options currently exist to address the neurological manifestations of ASMD
0
News & Notes
Inhibition of fatty acid amide hydrolase prevents pathology in neurovisceral acid sphingomyelinase deficiency by rescuing defective endocannabinoid signaling
Clinicopathologic correlations of a case report of a child with NPA
